Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Medicenna Therapeutics Corp announced that updated clinical data from its Phase 1/2 ABILITY-1 study will be presented at the 2024 Immunotherapy Bridge Conference. The study evaluates MDNA11, an innovative IL-2 super-agonist, in treating advanced solid tumors. This development underscores Medicenna’s commitment to advancing cancer immunotherapies.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
